SCHEMBL5676

SCHEMBL5676

Fc1ncccn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrogen Sulfide SCHEMBL27838627 0.96
SCHEMBL244401 0.96
Bicarbonate SCHEMBL2178826 0.84 NAPRT (0.48)
SCHEMBL4259192 0.82 HSP90AA1 (0.36)
Carbamic Acid SCHEMBL285340 0.80 NAPRT (0.50)
SCHEMBL29399188 0.65
SCHEMBL13217923 0.65
SCHEMBL21991617 0.65
SCHEMBL76868 0.65
SCHEMBL171853 0.64 HDAC8 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 19683 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144793-A1 METHODS OF TREATING CANCER AMGEN INC. (US) 2026-05-28 US claimed
EP-4735643-A1 METHODS FOR EARLY DETECTION OF CANCER Guardant Health, Inc. (US) 2026-05-06 EP claimed
US-20260120878-A1 METHODS FOR EARLY DETECTION OF CANCER GUARDANT HEALTH INC (US) 2026-04-30 US claimed
EP-4716553-A1 METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES AbbVie Manufacturing Management Unlimited Company (IE) 2026-04-01 EP claimed
US-12553903-B2 Ivaltinostat combination therapy for treating pancreatic cancer CG PHARMACEUTICALS, INC (US) 2026-02-17 US claimed
US-20260034212-A1 METHODS OF TREATING TUMORS BRISTOL-MYERS SQUIBB COMPANY (US) 2026-02-05 US claimed
US-20260021106-A1 COMBINATION THERAPY FOR TREATING CANCERS GEISTLICH PHARMA AG (CH) 2026-01-22 US claimed
US-12527838-B2 Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancel ALX Oncology Inc. (US) 2026-01-20 US claimed
US-20250376536-A1 MULTISPECIFIC ANTI-CD40 / ANTI-FAP ANTIBODIES AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2025-12-11 US claimed
US-20250368712-A1 METHODS OF TREATING CANCER ALX ONCOLOGY INC (US) 2025-12-04 US claimed
EP-0123907-B1 FLUOROPYRIMIDINE DERIVATIVES Chisso Corporation (JP) 1989-07-26 EP claimed
EP-0203505-B1 DISAZO METAL COMPLEX DYES BAYER AG (DE) 1989-05-24 EP claimed
EP-0290144-A1 Method of detecting incipient resistance to therapeutic agents in cancer patients City of Hope (US) 1988-11-09 EP claimed
EP-0203505-A1 Disazo metal complex dyes BAYER AG (DE) 1986-12-03 EP claimed
EP-0097289-B1 AZO DYESTUFFS BAYER AG (DE) 1986-10-15 EP claimed
EP-0041922-B1 PROCESS FOR THE PREPARATION OF AMINO-SUBSTITUTED 1-AMINO-8-HYDROXY-NAPHTHALENE-SULFONIC ACIDS CIBA-GEIGY AG (CH) 1984-10-03 EP claimed
EP-0043927-B1 PROCESS FOR PREPARING REACTIVE AZO DYESTUFFS BAYER AG (DE) 1984-05-16 EP claimed
EP-0097289-A2 Azo dyestuffs BAYER AG (DE) 1984-01-04 EP claimed
EP-0017172-B1 PROCESS FOR DYEING CELLULOSE FIBRES, AND FIBRE BLENDS THAT CONTAIN CELLULOSE/POLYESTER FIBRES, WITH REACTIVE DYES BAYER AG (DE) 1982-08-25 EP claimed
US-4024143-A Silylation of 5-fluoro-6-hydroxy or alkoxy pyrimidine PCR, INC. (US) 1977-05-17 US claimed